Cencora, Inc. $COR Stock Position Lowered by Islay Capital Management LLC

Posted by Brian Himes on Oct 20th, 2026

Islay Capital Management LLC trimmed its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 81.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 704 shares of the company’s stock after selling 3,068 shares during the period. Islay Capital Management LLC’s holdings in Cencora were worth $211,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in COR. Freedom Day Solutions LLC acquired a new stake in shares of Cencora in the third quarter valued at about $2,424,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Cencora by 0.8% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 29,500 shares of the company’s stock worth $8,857,000 after buying an additional 226 shares during the last quarter. CWA Asset Management Group LLC increased its stake in Cencora by 4.4% during the 3rd quarter. CWA Asset Management Group LLC now owns 2,217 shares of the company’s stock worth $666,000 after buying an additional 93 shares in the last quarter. Brown Lisle Cummings Inc. raised its holdings in shares of Cencora by 53.5% during the third quarter. Brown Lisle Cummings Inc. now owns 175 shares of the company’s stock valued at $53,000 after acquiring an additional 61 shares during the last quarter. Finally, IFP Advisors Inc lifted its position in shares of Cencora by 227.6% in the third quarter. IFP Advisors Inc now owns 20,264 shares of the company’s stock valued at $6,084,000 after acquiring an additional 14,078 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wells Fargo & Company raised their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Morgan Stanley raised their target price on Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Argus lifted their price target on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a report on Tuesday. Bank of America boosted their price target on shares of Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Finally, UBS Group cut their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a research report on Friday. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $366.31.

Read Our Latest Research Report on COR

Insider Buying and Selling

In other news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.38% of the stock is owned by company insiders.

Cencora Trading Up 0.6%

Shares of NYSE:COR traded up $1.91 during midday trading on Tuesday, reaching $341.91. 274,396 shares of the company’s stock were exchanged, compared to its average volume of 1,468,334. The stock has a market cap of $65.25 billion, a price-to-earnings ratio of 25.41, a P/E/G ratio of 1.75 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s 50 day simple moving average is $320.70 and its two-hundred day simple moving average is $303.48. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.

Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. During the same quarter last year, the firm posted $4.00 earnings per share. Cencora’s revenue was up 5.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Cencora, Inc. will post 17.87 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is presently 17.83%.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

Positive Sentiment: Argus raises price target and rating: Argus lifted its target for Cencora from $340 to $380 and assigned a Buy rating. The new target implies roughly 11% upside from the reported share price, providing the strongest immediate bullish catalyst. Cencora Inc (COR) PT Raised to $380 at Argus
Positive Sentiment: ETF buying signals institutional interest: Twenty-six ETFs added to their Cencora holdings on October 16. Although the purchases do not necessarily reflect a new fundamental development, they may support demand for the stock and investor sentiment. 26 ETFs Add to Cencora Holdings
Neutral Sentiment: Valuation remains a key focus: Coverage has highlighted Cencora’s approximately 25.36 price-to-earnings ratio as a valuation reference point. This suggests the stock is being assessed on whether its earnings growth can justify its current multiple. Cencora Valuation Anchor
Neutral Sentiment: Quarterly results are the next major catalyst: Recent coverage describes the stock trading ahead of quarterly results, leaving investors watching for updates on revenue, earnings, and guidance. Cencora’s latest reported quarter exceeded consensus estimates, with revenue up 5.1% year over year. Cencora Ahead of Quarterly Results
Negative Sentiment: UBS trims its target: UBS reduced its price target to $400. While the revised target remains above the reported trading level, the cut represents a more cautious view and partially counters Argus’s bullish revision. UBS Cuts Target for Cencora

About Cencora

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.